1. Home
  2. IMXI vs ANAB Comparison

IMXI vs ANAB Comparison

Compare IMXI & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo International Money Express Inc.

IMXI

International Money Express Inc.

HOLD

Current Price

$15.35

Market Cap

456.2M

Sector

Technology

ML Signal

HOLD

ANAB

AnaptysBio Inc.

HOLD

Current Price

$48.82

Market Cap

1.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IMXI
ANAB
Founded
1994
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Retail: Computer Software & Peripheral Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
456.2M
1.2B
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
IMXI
ANAB
Price
$15.35
$48.82
Analyst Decision
Buy
Buy
Analyst Count
3
11
Target Price
$16.67
$59.90
AVG Volume (30 Days)
241.4K
516.9K
Earning Date
11-10-2025
11-04-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
1.29
N/A
Revenue
$625,123,000.00
$169,467,000.00
Revenue This Year
N/A
$135.45
Revenue Next Year
$0.95
N/A
P/E Ratio
$11.91
N/A
Revenue Growth
N/A
196.42
52 Week Low
$8.58
$12.21
52 Week High
$21.41
$49.90

Technical Indicators

Market Signals
Indicator
IMXI
ANAB
Relative Strength Index (RSI) 60.67 75.12
Support Level $15.35 $43.92
Resistance Level $15.51 $47.86
Average True Range (ATR) 0.06 2.36
MACD -0.02 0.15
Stochastic Oscillator 39.62 88.43

Price Performance

Historical Comparison
IMXI
ANAB

About IMXI International Money Express Inc.

International Money Express Inc is a processor of money transfer services in the USA to the Latin America and the Caribbean (LAC) corridor. The company offers wire transfer, money order, Foreign exchange, and cash checking services, while the majority of the revenue is derived from wire transfer and money order fees. The firm's business is organized around one reportable segment that provides money remittance services between the U.S. and Canada to Mexico, Guatemala, and other countries in Latin America, Africa, and Asia.

About ANAB AnaptysBio Inc.

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

Share on Social Networks: